Sanofi (EPA:SAN) Share Price Passes Below 200-Day Moving Average – Time to Sell?

Shares of Sanofi (EPA:SAN) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of €79.02 and traded as low as €73.15. Sanofi shares last traded at €73.55, with a volume of 2,848,925 shares trading hands.

Key Headlines Impacting Sanofi

Here are the key news stories impacting Sanofi this week:

• Neutral Sentiment: The European Commission has launched formal antitrust proceedings into Sanofi over alleged disparaging or misleading marketing claims aimed at a rival flu vaccine in Germany and France. Sanofi under antitrust probe as European Commission kicks off formal proceedings
• Neutral Sentiment: Multiple reports say the EU probe could increase compliance costs and create headline risk, though the financial impact is still unclear at this early stage. EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims
• Neutral Sentiment: Sanofi was also highlighted in commentary about a Massachusetts World Cup-related investment, which appears more reputational/local-community focused than a direct earnings driver. Sanofi: World Cup investment will create lasting legacy in Massachusetts
• Neutral Sentiment: An analyst note said Dupixent risks may be overstated and that Sanofi’s valuation disconnect could present an opportunity, offering some offset to the regulatory concerns. Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity
• Negative Sentiment: The antitrust investigation itself is the main pressure point for Sanofi, since regulators are examining whether the company undermined a competitor’s flu vaccine with false or misleading marketing claims. Sanofi Suspected by EU of Disparaging a Flu Vaccine Rival

Sanofi Stock Up 1.8%

The stock has a fifty day moving average price of €76.26 and a 200-day moving average price of €78.98.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines.